Shortages of vital drugs, particularly cancer-fighting medication, have raised concerns in the US, where regulators often have to race to try to find replacements.
A recent report by the Federal Drug Administration (FDA) found that the number of important treatments that are difficult or impossible to find nearly tripled from 61 to 178 between 2005 and last year.
Most of the rare medications are for hospital use, including sterile injections, intravenous treatments, anesthetics and antibiotics. The products include both name-brand and generic drugs.
“FDA hears from patients and also from healthcare -professionals and organizations about the terrible impact the shortages have had,” spokeswoman Shelly Burgess said. “We continue to do all we can under our current authority to address shortages when they occur.”
However, the FDA’s efforts are hindered because it cannot force private pharmaceutical companies to produce certain drugs or even require them to notify the agency when they plan to discontinue one, Burgess said.
Last year, it was able to avert 38 shortages, mainly by persuading other manufacturers to produce the drugs or helping to resolve production issues.
However, a survey of 820 -hospitals carried out in June by the American Hospital Association found that almost all had run out of an important drug over the past six months.
Eighty percent said they had to delay patient treatments because of drug scarcity, and 70 percent said they administered less effective treatments.
“We really need to take a very careful look at what is going on. I have never seen anything like this and I have been a pharmacist for over 40 years,” said Mike Cohen, a pharmacist at the non-profit Safe Medical Practices.
The group recently surveyed 1,800 health professionals and found that a third of doctors and a fifth of pharmacists were aware of adverse reactions in their patients — including deaths — because of drug shortages.
Cynthia Reilly of the American Society of Health System Pharmacists said the “dramatic increase” in shortages is in part due to “quality issues.”
“In a lot of instances, the manufacturer is either having problems with the production lines or perhaps they found particular products in vials, so they have to do a recall,” she said.
Reilly fears the shortages will worsen as the pharmaceutical industry continues to consolidate, and as more companies stop producing generic drugs because they are less profitable.
“A few years ago, five companies were making a similar product. Now there is only one or two ... There are not a lot of companies to fill the gap,” she said.
She and other advocates believe new legislation to allow the FDA to force companies to alert it six months in advance of closing a production line would be helpful, because it would give the agency more time to find a substitute.
Two bills with broad support are currently under discussion in Congress.
Another problem is the so-called “gray market,” whereby distributors scoop up rare drugs and then charge hospitals exorbitant rates for them. Some drugs can fetch up to 1,000 times the normal price.
“We tell our members to contact their state attorney general. Unfortunately there is opportunity for unscrupulous behavior,” Reilly said.
ROCKY RELATIONS: The figures on residents come as Chinese tourist numbers drop following Beijing’s warnings to avoid traveling to Japan The number of Chinese residents in Japan has continued to rise, even as ties between the two countries have become increasingly fractious, data released on Friday showed. As of the end of December last year, the number of Chinese residents had increased by 6.5 percent from the previous year to 930,428. Chinese people accounted for 22.6 percent of all foreign residents in Japan, making them by far the largest group, Japanese Ministry of Justice data showed. Beijing has criticized Tokyo in increasingly strident terms since Japanese Prime Minister Sanae Takaichi last year suggested that a military conflict around Taiwan could
Japan is to downgrade its description of ties with China from “one of its most important” in an annual diplomatic report, according to a draft reviewed by Reuters, as relations with Beijing worsen. This year’s Diplomatic Bluebook, which Japanese Prime Minister Sanae Takaichi’s government is expected to approve next month, would instead describe China as an important neighbor and the relationship as “strategic” and “mutually beneficial.” The draft cites a series of confrontations with Beijing over the past year, including export controls on rare earths, radar lock-ons targeting Japanese military aircraft and increased pressure around Taiwan. The shift in tone underscores a deterioration
A retired US colonel behind a privately financed rocket launch site in the Dominican Republic sees the project as a response to China’s dominance of the space race in Latin America. Florida-based Launch on Demand is slated to begin building a US$600 million facility in a remote region near the border with Haiti late this year. The project is designed to meet surging demand for the heavy-lift rockets needed to put clusters of satellites into orbit. It is also an answer to China’s growing presence in the region, said CEO Burton Catledge, a former commander of the US Air Force’s 45th Operations
Germany is considering Australia’s Ghost Bat robot fighter as it looks to select a combat drone to modernize its air force, German Minister of Defense Boris Pistorius said yesterday. Germany has said it wants to field hundreds of uncrewed fighter jets by 2029, and would make a decision soon as it considers a range of German, European and US projects developing so-called “collaborative combat aircraft.” Australia has said it will integrate the Ghost Bat, jointly developed by Boeing Australia and the Royal Australian Air Force, into its military after a successful weapons test last year. After inspecting the Ghost Bat in Queensland yesterday,
RSS